

Pedro Romero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7031521/publications.pdf>

Version: 2024-02-01

313
papers

27,298
citations

5574

82
h-index

7745

150
g-index

322
all docs

322
docs citations

322
times ranked

30154
citing authors

#	ARTICLE	IF	CITATIONS
1	BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. <i>Journal of Experimental Medicine</i> , 1999, 189, 1747-1756.	8.5	1,213
2	TLR3 Deficiency in Patients with Herpes Simplex Encephalitis. <i>Science</i> , 2007, 317, 1522-1527.	12.6	970
3	Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation. <i>Immunity</i> , 2011, 34, 213-223.	14.3	810
4	Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. <i>Journal of Clinical Investigation</i> , 2011, 121, 2350-2360.	8.2	707
5	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>Journal of Clinical Investigation</i> , 2005, 115, 739-746.	8.2	569
6	Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. <i>Nature</i> , 1989, 341, 323-326.	27.8	501
7	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6140-6145.	7.1	498
8	Tumour immunity: effector response to tumour and role of the microenvironment. <i>Lancet</i> , The, 2008, 371, 771-783.	13.7	476
9	Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1998, 188, 1641-1650.	8.5	475
10	Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 425-441.	27.6	452
11	High Frequencies of Naive Melan-a/Mart-1-Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals. <i>Journal of Experimental Medicine</i> , 1999, 190, 705-716.	8.5	447
12	A synthetic vaccine protects humans against challenge with asexual blood stages of <i>Plasmodium falciparum</i> malaria. <i>Nature</i> , 1988, 332, 158-161.	27.8	415
13	High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo. <i>Journal of Experimental Medicine</i> , 1998, 188, 1203-1208.	8.5	408
14	Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. <i>Cancer Research</i> , 2004, 64, 2865-2873.	0.9	351
15	Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. <i>Arthritis and Rheumatism</i> , 2008, 58, 2307-2317.	6.7	351
16	Four Functionally Distinct Populations of Human Effector-Memory CD8+ T Lymphocytes. <i>Journal of Immunology</i> , 2007, 178, 4112-4119.	0.8	347
17	Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. <i>Journal of Clinical Investigation</i> , 2014, 124, 1810-1820.	8.2	340
18	Induction of protective immunity against experimental infection with malaria using synthetic peptides. <i>Nature</i> , 1987, 328, 629-632.	27.8	296

#	ARTICLE	IF	CITATIONS
19	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. <i>Frontiers in Immunology</i> , 2019, 10, 925.	4.8	288
20	MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer. <i>Immunity</i> , 2013, 38, 742-753.	14.3	278
21	Human natural Treg microRNA signature: Role of microRNA-31 and microRNA-21 in FOXP3 expression. <i>European Journal of Immunology</i> , 2009, 39, 1608-1618.	2.9	252
22	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. <i>Journal of Clinical Investigation</i> , 2010, 120, 157-167.	8.2	252
23	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. <i>Nature Reviews Immunology</i> , 2014, 14, 768-774.	22.7	248
24	Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression. <i>Journal of Immunology</i> , 2000, 164, 1148-1152.	0.8	232
25	CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. <i>Nature</i> , 1995, 373, 353-356.	27.8	231
26	Cross-presenting human $\gamma\delta$ T cells induce robust CD8 $\alpha\beta$ T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2307-2312.	7.1	229
27	Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression. <i>Cancer Research</i> , 2011, 71, 5976-5986.	0.9	223
28	CD8+ cytolytic T cell clones derived against the <i>Plasmodium yoelii</i> circumsporozoite protein protect against malaria. <i>International Immunology</i> , 1991, 3, 579-585.	4.0	216
29	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. , 1996, 66, 162-169.		200
30	Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development. <i>Cell Metabolism</i> , 2019, 29, 348-361.e6.	16.2	200
31	OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. <i>Nature Immunology</i> , 2000, 1, 502-509.	14.5	198
32	Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function. <i>Journal of Immunology</i> , 2010, 184, 4936-4946.	0.8	196
33	Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. <i>Oncogene</i> , 2002, 21, 5213-5223.	5.9	194
34	Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 303-315.	4.2	193
35	Toll-like Receptor 3 Expressed by Melanoma Cells as a Target for Therapy?. <i>Clinical Cancer Research</i> , 2007, 13, 4565-4574.	7.0	184
36	In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma-Specific Cytolytic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1999, 190, 775-782.	8.5	179

#	ARTICLE	IF	CITATIONS
37	“MIATA” Minimal Information about T Cell Assays. Immunity, 2009, 31, 527-528.	14.3	178
38	The Cooperative Induction of Hypoxia-Inducible Factor-1 α and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis. Journal of Immunology, 2009, 182, 3510-3521.	0.8	175
39	Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells. Cancer Research, 2012, 72, 4629-4641.	0.9	168
40	Ex vivo characterization of human CD8 $^{+}$ T subsets with distinct replicative history and partial effector functions. Blood, 2003, 102, 1779-1787.	1.4	167
41	Metabolic and epigenetic regulation of T-cell exhaustion. Nature Metabolism, 2020, 2, 1001-1012.	11.9	167
42	Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes. Cancer Immunology Research, 2014, 2, 436-447.	3.4	165
43	The Human Vaccines Project: A roadmap for cancer vaccine development. Science Translational Medicine, 2016, 8, 334ps9.	12.4	162
44	Metabolic reprogramming of terminally exhausted CD8 $^{+}$ T cells by IL-10 enhances anti-tumor immunity. Nature Immunology, 2021, 22, 746-756.	14.5	160
45	Metabolic Control of CD8 $^{+}$ T Cell Fate Decisions and Antitumor Immunity. Trends in Molecular Medicine, 2018, 24, 30-48.	6.7	158
46	New Generation Vaccine Induces Effective Melanoma-Specific CD8 $^{+}$ T Cells in the Circulation but Not in the Tumor Site. Journal of Immunology, 2006, 177, 1670-1678.	0.8	157
47	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science Advances, 2021, 7, .	10.3	157
48	Toll-like receptors $^{\text{TM}}$ two-edged sword: when immunity meets apoptosis. European Journal of Immunology, 2007, 37, 3311-3318.	2.9	156
49	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunological Reviews, 2002, 188, 81-96.	6.0	146
50	The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. Cell Stem Cell, 2019, 24, 405-418.e7.	11.1	143
51	Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans. Journal of Experimental Medicine, 2002, 195, 485-494.	8.5	136
52	Cooperation of Human Tumor-Reactive CD4 $^{+}$ and CD8 $^{+}$ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR. Immunity, 2005, 22, 117-129.	14.3	136
53	Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3849-3854.	7.1	136
54	Ex Vivo IFN- γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases. Journal of Immunology, 2001, 166, 7634-7640.	0.8	135

#	ARTICLE	IF	CITATIONS
55	CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide. Journal of Immunology, 2002, 168, 1212-1218.	0.8	135
56	Mitochondria-Endoplasmic Reticulum Contact Sites Function as Immunometabolic Hubs that Orchestrate the Rapid Recall Response of Memory CD8+ T Cells. Immunity, 2018, 48, 542-555.e6.	14.3	133
57	Quantitation of antigen-reactive T cells in peripheral blood by IFN γ -ELISPOT assay and chromium-release assay: a four-centre comparative trial. Journal of Immunological Methods, 2000, 244, 81-89.	1.4	131
58	Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. Journal of Immunotherapy, 2010, 33, 848-858.	2.4	131
59	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
60	Sensitive and frequent identification of high avidity neo-epitope-specific CD8 + T cells in immunotherapy-naïve ovarian cancer. Nature Communications, 2018, 9, 1092.	12.8	122
61	Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness. Journal of Biological Chemistry, 2012, 287, 23068-23078.	3.4	121
62	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
63	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. Oncoimmunology, 2015, 4, e998538.	4.6	119
64	Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte-defined Peptide Derived from the Tumor Antigen MAGE-3. Journal of Experimental Medicine, 1999, 189, 895-906.	8.5	116
65	NLR5 Deficiency Selectively Impairs MHC Class I- Dependent Lymphocyte Killing by Cytotoxic T Cells. Journal of Immunology, 2012, 188, 3820-3828.	0.8	116
66	Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity. Journal of Immunology, 2002, 168, 4231-4240.	0.8	113
67	<i>In vivo</i> imaging of T cell delivery to tumors after adoptive transfer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12457-12461.	7.1	113
68	Human Effector CD8+ T Lymphocytes Express TLR3 as a Functional Coreceptor. Journal of Immunology, 2006, 177, 8708-8713.	0.8	112
69	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. European Journal of Immunology, 1999, 29, 1990-1999.	2.9	111
70	Mammalian Target of Rapamycin Complex 2 Controls CD8 ⁺ T Cell Memory Differentiation in a Foxo1-Dependent Manner. Cell Reports, 2016, 14, 1206-1217.	6.4	111
71	SHP-1 phosphatase activity counteracts increased T cell receptor affinity. Journal of Clinical Investigation, 2013, 123, 1044-1056.	8.2	109
72	Adjuvant Immunization of HLA-A2 ⁺ Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses. Journal of Clinical Oncology, 2003, 21, 1562-1573.	1.6	107

#	ARTICLE	IF	CITATIONS
73	Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma. <i>Journal of Immunology</i> , 2002, 168, 1717-1722.	0.8	106
74	TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1607-1614.	0.9	105
75	Enrichment of Human CD4+ VÎ±24/VÎ±211 Invariant NKT Cells in Intrahepatic Malignant Tumors. <i>Journal of Immunology</i> , 2009, 182, 5140-5151.	0.8	103
76	A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. <i>Immunogenetics</i> , 1996, 43, 377-383.	2.4	98
77	In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. <i>European Journal of Immunology</i> , 2002, 32, 731.	2.9	96
78	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. <i>Blood</i> , 2007, 110, 3564-3572.	1.4	95
79	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma. <i>Cancer Research</i> , 2004, 64, 2192-2198.	0.9	94
80	Prognostic value of arginaseâ€œ expression and regulatory Tâ€œcell infiltration in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2013, 132, E85-93.	5.1	94
81	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2019, 7, 707-718.	3.4	94
82	T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. <i>Journal of Immunological Methods</i> , 1992, 155, 95-99.	1.4	91
83	Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans. <i>Journal of Experimental Medicine</i> , 2002, 196, 207-216.	8.5	90
84	Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma. <i>Journal of Immunology</i> , 2005, 174, 1709-1716.	0.8	89
85	Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. <i>EBioMedicine</i> , 2016, 4, 50-61.	6.1	89
86	Molecular Design of the CÎ±Î² Interface Favors Specific Pairing of Introduced TCRÎ±Î² in Human T Cells. <i>Journal of Immunology</i> , 2008, 180, 391-401.	0.8	87
87	Harmonization of Immune Biomarker Assays for Clinical Studies. <i>Science Translational Medicine</i> , 2011, 3, 108ps44.	12.4	87
88	Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity. <i>Cancer Research</i> , 2013, 73, 6597-6608.	0.9	86
89	Letter to the editor. <i>International Journal of Cancer</i> , 1993, 54, 527-528.	5.1	84
90	Tetramer-Guided Analysis of TCR Î²2-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients. <i>Journal of Immunology</i> , 2000, 165, 533-538.	0.8	84

#	ARTICLE	IF	CITATIONS
91	The Activatory Receptor 2B4 Is Expressed In Vivo by Human CD8+ Effector $\gamma\delta$ T Cells. <i>Journal of Immunology</i> , 2001, 167, 6165-6170.	0.8	82
92	MicroRNA Profile of Circulating CD4-positive Regulatory T Cells in Human Adults and Impact of Differentially Expressed MicroRNAs on Expression of Two Genes Essential to Their Function. <i>Journal of Biological Chemistry</i> , 2012, 287, 9910-9922.	3.4	80
93	CD8 $\gamma\delta$ Increases CD8 Coreceptor Function and Participation in TCR α -Ligand Binding. <i>Journal of Experimental Medicine</i> , 1996, 184, 2439-2444.	8.5	79
94	Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. <i>Trends in Molecular Medicine</i> , 1998, 4, 305-312.	2.6	78
95	A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination. <i>Journal of Immunology</i> , 2006, 177, 1338-1348.	0.8	78
96	Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma. <i>Journal of Immunology</i> , 2000, 165, 7253-7261.	0.8	77
97	Lack of tumor recognition by hTERT peptide 540-548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. <i>European Journal of Immunology</i> , 2001, 31, 2642-2651.	2.9	76
98	Prevalent Role of TCR γ -Chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen. <i>Journal of Immunology</i> , 2003, 170, 5103-5109.	0.8	76
99	Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2076.	4.8	76
100	Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue. <i>Journal of Immunology</i> , 2000, 164, 1125-1131.	0.8	75
101	Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes. <i>Journal of Immunology</i> , 2001, 167, 3276-3284.	0.8	75
102	gp100209 α -2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells. <i>Clinical Cancer Research</i> , 2004, 10, 668-680.	7.0	74
103	Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	74
104	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. <i>Frontiers in Immunology</i> , 2016, 7, 573.	4.8	73
105	Enforced PGC-1 α expression promotes CD8 T cell fitness, memory formation and antitumor immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1761-1771.	10.5	73
106	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1918.	4.8	72
107	Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 249-255.	4.2	70
108	Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. <i>Cancer Research</i> , 2002, 62, 1743-50.	0.9	70

#	ARTICLE	IF	CITATIONS
109	Clonotype Selection and Composition of Human CD8 T Cells Specific for Persistent Herpes Viruses Varies with Differentiation but Is Stable Over Time. <i>Journal of Immunology</i> , 2009, 183, 319-331.	0.8	69
110	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. <i>European Journal of Immunology</i> , 2011, 41, 2217-2228.	2.9	69
111	Virus-like particles induce robust human T-helper cell responses. <i>European Journal of Immunology</i> , 2012, 42, 330-340.	2.9	69
112	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. <i>Journal of Translational Medicine</i> , 2014, 12, 97.	4.4	69
113	CD127+ innate lymphoid cells are dysregulated in treatment naive acute myeloid leukemia patients at diagnosis. <i>Haematologica</i> , 2015, 100, e257-e260.	3.5	69
114	Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR. <i>Journal of Immunology</i> , 2002, 168, 1167-1171.	0.8	67
115	Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. <i>Journal of Translational Medicine</i> , 2011, 9, 44.	4.4	67
116	Circulating MELAN-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. <i>International Journal of Cancer</i> , 1998, 78, 699-706.	5.1	66
117	Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2011, 128, 2625-2634.	5.1	66
118	I \pm 3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells. <i>Journal of Immunology</i> , 2003, 171, 1844-1849.	0.8	65
119	Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1795-1805.	4.2	65
120	The mitochondrial pyruvate carrier regulates memory T-cell differentiation and antitumor function. <i>Cell Metabolism</i> , 2022, 34, 731-746.e9.	16.2	63
121	Mammalian Target of Rapamycin Complex 1 Orchestrates Invariant NKT Cell Differentiation and Effector Function. <i>Journal of Immunology</i> , 2014, 193, 1759-1765.	0.8	62
122	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1859-1868.	6.4	62
123	High Frequency of Functionally Active Melan-A-Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma. <i>Cancer Research</i> , 2004, 64, 6319-6326.	0.9	60
124	Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1701-1713.	4.2	60
125	Leishmania major infection in mice primes for specific major histocompatibility complex class I-restricted CD8+ cytotoxic T cell responses. <i>European Journal of Immunology</i> , 1994, 24, 2813-2817.	2.9	58
126	Positional Scanning-Synthetic Peptide Library-Based Analysis of Self- and Pathogen-Derived Peptide Cross-Reactivity with Tumor-Reactive Melan-A-Specific CTL. <i>Journal of Immunology</i> , 2002, 169, 5696-5707.	0.8	57

#	ARTICLE	IF	CITATIONS
127	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
128	The Human T Cell Response to Melanoma Antigens. Advances in Immunology, 2006, 92, 187-224.	2.2	56
129	Dextramers: New generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. Journal of Immunological Methods, 2006, 310, 136-148.	1.4	55
130	Ex vivo Detectable Human CD8 T-Cell Responses to Cancer-Testis Antigens. Cancer Research, 2006, 66, 1912-1916.	0.9	55
131	The Majority of Autologous Cytolytic T-Lymphocyte Clones Derived from Peripheral Blood Lymphocytes of a Melanoma Patient Recognize an Antigenic Peptide Derived from Gene Pmel17/gp100. Journal of Investigative Dermatology, 1996, 107, 63-67.	0.7	54
132	Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends in Immunology, 2002, 23, 325-328.	6.8	53
133	Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints. Cancer Research, 2018, 78, 3604-3618.	0.9	53
134	CART cells are prone to Fas- and DR5-mediated cell death. , 2018, 6, 71.		53
135	Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: Advantages and limitations. Cytometry, 2002, 48, 97-105.	1.8	51
136	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nature Immunology, 2019, 20, 206-217.	14.5	51
137	Structural analysis of TCR-ligand interactions studied on H-2Kd-restricted cloned CTL specific for a photoreactive peptide derivative. Immunity, 1995, 3, 51-63.	14.3	50
138	Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Seminars in Cancer Biology, 2003, 13, 461-472.	9.6	50
139	Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8 ⁺ and CD4 ⁺ T-cell responses with multiple specificities including a novel DR7-restricted epitope. OncoImmunology, 2016, 5, e1216290.	4.6	50
140	Specific binding of antigenic peptides to cell-associated MHC class I molecules. Nature, 1991, 351, 72-74.	27.8	49
141	Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. International Immunology, 1999, 11, 1971-1980.	4.0	49
142	The Era of Cytotoxic CD4 T Cells. Frontiers in Immunology, 2022, 13, 867189.	4.8	49
143	Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. Journal of Immunological Methods, 2000, 237, 159-173.	1.4	48
144	Human CD8+ T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. European Journal of Immunology, 2001, 31, 459-466.	2.9	48

#	ARTICLE	IF	CITATIONS
145	Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers. <i>Journal of Immunology</i> , 2006, 177, 6769-6779.	0.8	48
146	Fine Structural Variations of $\alpha\beta$ TCRs Selected by Vaccination with Natural versus Altered Self-Antigen in Melanoma Patients. <i>Journal of Immunology</i> , 2009, 183, 5397-5406.	0.8	48
147	Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells. <i>Blood</i> , 2010, 115, 5154-5163.	1.4	48
148	Cancer Vaccine Design: A Novel Bacterial Adjuvant for Peptide-Specific CTL Induction. <i>Journal of Immunology</i> , 2001, 166, 4612-4619.	0.8	47
149	Expression Hierarchy of T Cell Epitopes from Melanoma Differentiation Antigens: Unexpected High Level Presentation of Tyrosinase-HLA-A2 Complexes Revealed by Peptide-Specific, MHC-Restricted, TCR-Like Antibodies. <i>Journal of Immunology</i> , 2009, 182, 6328-6341.	0.8	47
150	Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model. <i>Cell Death and Disease</i> , 2016, 7, e2243-e2243.	6.3	47
151	Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. <i>Journal of Immunological Methods</i> , 2006, 309, 192-199.	1.4	46
152	TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency. <i>JCI Insight</i> , 2017, 2, .	5.0	46
153	A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy. <i>Journal of Immunology</i> , 2001, 167, 5852-5861.	0.8	44
154	PPAR δ drives IL-33-dependent ILC2 pro-tumoral functions. <i>Nature Communications</i> , 2021, 12, 2538.	12.8	44
155	Redirection of T Cells by Delivering a Transgenic Mouse-Derived MDM2 Tumor Antigen-Specific TCR and its Humanized Derivative Is Governed by the CD8 Coreceptor and Affects Natural Human TCR Expression. <i>Immunologic Research</i> , 2006, 34, 67-87.	2.9	43
156	Recent advances and hurdles in melanoma immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 711-723.	3.3	43
157	Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre-injection of IFA alone. <i>European Journal of Immunology</i> , 1994, 24, 1458-1462.	2.9	42
158	Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. <i>International Immunopharmacology</i> , 2001, 1, 1235-1247.	3.8	42
159	Sensitive Gene Expression Profiling of Human T Cell Subsets Reveals Parallel Post-Thymic Differentiation for CD4+ and CD8+ Lineages. <i>Journal of Immunology</i> , 2007, 179, 7406-7414.	0.8	41
160	Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma. <i>Molecular Therapy</i> , 2008, 16, 985-994.	8.2	41
161	Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon- γ ELISPOT Assays for Patient Immune Monitoring. <i>Journal of Immunotherapy</i> , 2004, 27, 298-308.	2.4	40
162	Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts. <i>Cancer Research</i> , 2009, 69, 8085-8093.	0.9	40

#	ARTICLE	IF	CITATIONS
163	Dendritic Cell-Specific Antigen Delivery by Coronavirus Vaccine Vectors Induces Long-Lasting Protective Antiviral and Antitumor Immunity. MBio, 2010, 1, .	4.1	40
164	NLR5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nature Communications, 2016, 7, 10554.	12.8	40
165	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances, 2019, 3, 3674-3687.	5.2	40
166	Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Research, 2003, 63, 5601-6.	0.9	40
167	HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT. Parasite Immunology, 2000, 22, 501-514.	1.5	39
168	Distinct sets of $\alpha\beta$ TCRs confer similar recognition of tumor antigen NY-ESO-1₁₅₇₋₁₆₅ by interacting with its central Met/Trp residues. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15010-15015.	7.1	39
169	Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Seminars in Immunology, 2010, 22, 144-154.	5.6	39
170	CD73 expression and clinical significance in human metastatic melanoma. Oncotarget, 2018, 9, 26659-26669.	1.8	39
171	The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. International Immunology, 1991, 3, 1035-1042.	4.0	38
172	Generation and characterization of malaria-specific human CD8+ lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentation by liver cells. European Journal of Immunology, 2000, 30, 3079-3088.	2.9	38
173	Expression of melan-a/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. International Journal of Cancer, 2001, 95, 73-77.	5.1	38
174	Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity. European Journal of Immunology, 2002, 32, 2292.	2.9	37
175	A microRNA profile of human CD8+ regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes. Journal of Translational Medicine, 2014, 12, 218.	4.4	37
176	Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clinical Cancer Research, 2003, 9, 669-77.	7.0	37
177	Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Immunology Letters, 1990, 25, 27-31.	2.5	36
178	Optimum in vitro expansion of human antigen-specific CD8+ T cells for adoptive transfer therapy. Clinical and Experimental Immunology, 2005, 142, 292-302.	2.6	36
179	Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunity, 2004, 4, 4.	3.2	36
180	CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival. Cancer Research, 2019, 79, 5245-5259.	0.9	35

#	ARTICLE	IF	CITATIONS
181	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 2121.	4.8	35
182	CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 747-760.	4.2	34
183	Reverse immunology approach for the identification of CD8 Tâ€cellâ€defined antigens: Advantages and hurdles. <i>Immunology and Cell Biology</i> , 2006, 84, 318-330.	2.3	32
184	Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. <i>European Journal of Cancer</i> , 2020, 135, 173-182.	2.8	32
185	An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. <i>Oncotarget</i> , 2016, 7, 21199-21221.	1.8	32
186	CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. <i>Immunology Letters</i> , 1995, 46, 199-205.	2.5	31
187	PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. <i>Journal of Immunology</i> , 2018, 201, 792-803.	0.8	31
188	Fibroblast Activation Protein Î±-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 4036-4053.	7.0	31
189	Potential target antigens for immunotherapy in human pancreatic cancer. <i>Cancer Letters</i> , 2007, 252, 290-298.	7.2	30
190	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1199-1211.	4.2	30
191	IL-21â€Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factorâ€Dependent Manner. <i>Journal of Immunology</i> , 2016, 197, 85-96.	0.8	30
192	Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirusâ€associated genital tumors. <i>International Journal of Cancer</i> , 2011, 129, 762-772.	5.1	29
193	Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multi-peptide melanoma vaccine. <i>Cancer Immunity</i> , 2003, 3, 15.	3.2	29
194	LiveCount Assay: Concomitant measurement of cytolytic activity and phenotypic characterisation of CD8+ T-cells by flow cytometry. <i>Journal of Immunological Methods</i> , 2006, 311, 31-46.	1.4	28
195	Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 839-847.	4.2	28
196	Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 15318-15323.	7.1	28
197	Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells. <i>Journal of Leukocyte Biology</i> , 2020, 108, 723-737.	3.3	28
198	Toward improved immunocompetence of adoptively transferred CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1467-1469.	8.2	28

#	ARTICLE	IF	CITATIONS
199	High frequencies of functionally impaired cytokeratin 18-specific CD8+ Tâ€œcells in healthy HLA-A2+ donors. <i>European Journal of Immunology</i> , 2005, 35, 2876-2885.	2.9	27
200	Combination of Transient Lymphodepletion With Busulfan and Fludarabine and Peptide Vaccination in a Phase I Clinical Trial for Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2007, 30, 240-250.	2.4	27
201	Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. <i>Frontiers in Immunology</i> , 2019, 10, 294.	4.8	27
202	CD73 expression in normal and pathological human hepatobiliopancreatic tissues. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 467-478.	4.2	27
203	Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 340.	4.8	27
204	Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 735-741.	0.8	26
205	Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. <i>European Journal of Immunology</i> , 2000, 30, 3165-3170.	2.9	26
206	Subcellular Localization of the Melanoma-associated Protein Melan-AMART-1 Influences the Processing of Its HLA-A2-restricted Epitope. <i>Journal of Biological Chemistry</i> , 2001, 276, 43189-43196.	3.4	26
207	In Vivo Persistence of Codominant Human CD8+T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. <i>Journal of Immunology</i> , 2007, 179, 2368-2379.	0.8	26
208	Lighting up the tumor fire with low-dose irradiation. <i>Trends in Immunology</i> , 2022, 43, 173-179.	6.8	26
209	Allorestricted T lymphocytes with a high avidity Tâ€œcell receptor towards NYâ€œESOâ€œ1 have potent antiâ€œtumor activity. <i>International Journal of Cancer</i> , 2009, 125, 649-655.	5.1	25
210	A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. <i>Journal of Translational Medicine</i> , 2011, 9, 108.	4.4	25
211	Differential T cell receptor photoaffinity labeling among H-2Kd restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. Labeling of the alpha-chain correlates with J alpha segment usage.. <i>Journal of Experimental Medicine</i> , 1993, 177, 1247-1256.	8.5	24
212	Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscleâ€œInvasive Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 717-725.	7.0	24
213	Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth. <i>Frontiers in Oncology</i> , 2018, 8, 356.	2.8	24
214	MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 1013-1024.	3.4	24
215	Current State of Vaccine Therapies in Nonâ€œSmall-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S28-S36.	2.6	23
216	MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 23-35.	4.2	23

#	ARTICLE	IF	CITATIONS
217	Rationale for immunological approaches to breast cancer therapy. <i>Breast</i> , 2018, 37, 187-195.	2.2	23
218	HLA Photoaffinity Labeling Reveals Overlapping Binding of Homologous Melanoma-associated Gene Peptides by HLA-A1, HLA-A29, and HLA-B44. <i>Journal of Biological Chemistry</i> , 1996, 271, 12463-12471.	3.4	22
219	Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. <i>European Journal of Immunology</i> , 2002, 32, 3285-3293.	2.9	22
220	Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex. <i>Journal of Immunology</i> , 2006, 176, 2330-2336.	0.8	22
221	Valproate Treatment of Human Cord Blood CD4-positive Effector T Cells Confers on Them the Molecular Profile (MicroRNA Signature and FOXP3 Expression) of Natural Regulatory CD4-positive Cells through Inhibition of Histone Deacetylase. <i>Journal of Biological Chemistry</i> , 2010, 285, 20481-20491.	3.4	22
222	Piezoresistive Membrane Surface Stress Sensors for Characterization of Breath Samples of Head and Neck Cancer Patients. <i>Sensors</i> , 2016, 16, 1149.	3.8	22
223	MHC class I H-2Kd-restricted antigenic peptides: additional constraints for the binding motif. <i>International Immunology</i> , 1993, 5, 1489-1492.	4.0	21
224	Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. <i>Blood</i> , 2003, 102, 1241-1248.	1.4	21
225	Final Antigenic Melan-A Peptides Produced Directly by the Proteasomes Are Preferentially Selected for Presentation by HLA-A*0201 in Melanoma Cells. <i>Journal of Immunology</i> , 2004, 173, 6033-6040.	0.8	21
226	Melanoma Immunotherapy: Past, Present, and Future. <i>Current Pharmaceutical Design</i> , 2005, 11, 3461-3473.	1.9	21
227	A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide. <i>Journal of Immunology</i> , 2007, 179, 7635-7645.	0.8	21
228	Induction of Circulating Tumor-reactive CD8+ T Cells After Vaccination of Melanoma Patients With the gp100209-2M Peptide. <i>Journal of Immunotherapy</i> , 2007, 30, 533-543.	2.4	21
229	Impact of 3 Different Short-term Chemotherapy Regimens on Lymphocyte-depletion and Reconstitution in Melanoma Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 723-734.	2.4	21
230	Curtailed T _H 1 cell activation curbs effector differentiation and generates CD8 ⁺ T cells with a naturally occurring memory stem cell phenotype. <i>European Journal of Immunology</i> , 2017, 47, 1468-1476.	2.9	21
231	An Immunomodulatory Gallotanin-Rich Fraction From <i>Caesalpinia spinosa</i> Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 584959.	4.8	21
232	Immunosuppressive Mediators Impair Proinflammatory Innate Lymphoid Cell Function in Human Malignant Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 556-564.	3.4	21
233	Differential Roles of T Cell Receptor α and β Chains in Ligand Binding Among H-2Kd-restricted Cytolytic T Lymphocyte Clones Specific for a Photoreactive <i>Plasmodium berghei</i> Circumsporozoite Peptide Derivative. <i>Journal of Biological Chemistry</i> , 1997, 272, 8505-8514.	3.4	19
234	Human Thymus Exports Naive CD8 T Cells That Can Home to Nonlymphoid Tissues. <i>Journal of Immunology</i> , 2004, 172, 2773-2777.	0.8	19

#	ARTICLE	IF	CITATIONS
235	Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1979-1991.	4.2	19
236	Saponins from the Spanish saffron <i>Crocus sativus</i> are efficient adjuvants for protein-based vaccines. <i>Vaccine</i> , 2012, 30, 388-397.	3.8	19
237	Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ Tumor-reactive T-Cell Ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone. <i>Cancer Research</i> , 2002, 62, 2058-63.	0.9	19
238	Loss of single HLA Class I allospecificities in melanoma cells due to selective genomic abbreviations. <i>International Journal of Cancer</i> , 2002, 99, 82-87.	5.1	18
239	Dominant Human CD8 T Cell Clonotypes Persist Simultaneously as Memory and Effector Cells in Memory Phase. <i>Journal of Immunology</i> , 2009, 182, 6718-6726.	0.8	18
240	Toll-like receptor 3 is necessary for dsRNA adjuvant effects. <i>Vaccine</i> , 2009, 27, 1841-1847.	3.8	18
241	Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPAR γ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth. <i>Cancer Research</i> , 2018, 78, 6447-6461.	0.9	18
242	Gain of HIF1 Activity and Loss of miRNA <i>let-7d</i> Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis. <i>Cancer Research</i> , 2021, 81, 594-605.	0.9	18
243	CD40 Agonist Targeted to Fibroblast Activation Protein \pm Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4054-4065.	7.0	18
244	Decreased specific CD8+ T α cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. <i>European Journal of Immunology</i> , 2006, 36, 1805-1814.	2.9	17
245	IL-12 Controls Cytotoxicity of a Novel Subset of Self-Antigen-Specific Human CD28+ Cytolytic T Cells. <i>Journal of Immunology</i> , 2007, 178, 3566-3574.	0.8	17
246	Induction of human papillomavirus oncogene-specific CD8 T cell effector responses in the genital mucosa of vaccinated mice. <i>International Journal of Cancer</i> , 2010, 126, 2469-2478.	5.1	17
247	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. <i>Onc Immunology</i> , 2015, 4, e1029702.	4.6	17
248	Vaccination of Melanoma Patients With Melan-A/Mart-1 Peptide and Klebsiella Outer Membrane Protein P40 as an Adjuvant. <i>Journal of Immunotherapy</i> , 2009, 32, 875-883.	2.4	16
249	Vaccination Route Matters for Mucosal Tumors. <i>Science Translational Medicine</i> , 2013, 5, 172fs4.	12.4	16
250	iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. , 2014, 2, 39.		16
251	Methods for the Ex Vivo Characterization of Human CD8 ⁺ T Subsets Based on Gene Expression and Replicative History Analysis. , 2005, 109, 265-284.		15
252	Recent advances in tumour antigen-specific therapy: In vivo veritas. <i>International Journal of Cancer</i> , 2005, 113, 173-178.	5.1	15

#	ARTICLE	IF	CITATIONS
253	High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4320-4331.	7.0	15
254	miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 111-123.	4.4	15
255	Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e78686.	2.5	15
256	Distinct Mechanisms Control Human Naive and Antigen-Experienced CD8+ T Lymphocyte Proliferation. <i>Journal of Immunology</i> , 2006, 176, 2173-2182.	0.8	14
257	Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. <i>International Immunology</i> , 2008, 20, 1087-1096.	4.0	14
258	Human melanoma-specific CD8 ⁺ T-cells from metastases are capable of antigen-specific degranulation and cytotoxicity directly ex vivo. <i>Oncolmunology</i> , 2012, 1, 467-530.	4.6	14
259	Intravaginal and Subcutaneous Immunization Induced Vaccine Specific CD8 T Cells and Tumor Regression in the Bladder. <i>Journal of Urology</i> , 2014, 191, 814-822.	0.4	14
260	Epitope located in N-glycans impair the MHC-II epitope generation and presentation. <i>Electrophoresis</i> , 2016, 37, 1448-1460.	2.4	14
261	Amino Acid Identity and/or Position Determines the Proteasomal Cleavage of the HLA-A*0201-restricted Peptide Tumor Antigen MAGE-3271-279. <i>Journal of Biological Chemistry</i> , 2000, 275, 26892-26897.	3.4	13
262	Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. <i>Seminars in Immunopathology</i> , 1996, 18, 185-198.	4.0	12
263	Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8 ⁺ T cells. <i>Oncolmunology</i> , 2017, 6, e1318234.	4.6	12
264	Efficient in vivo induction of CTL by cell-associated covalent H-2Kd-peptide complexes. <i>Journal of Immunological Methods</i> , 1994, 171, 73-84.	1.4	11
265	Reduced L-selectin (CD62L) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. <i>Cellular Immunology</i> , 2004, 227, 93-102.	3.0	11
266	Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1795-1805.	4.2	11
267	Local <i>Salmonella</i> immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. <i>Oncolmunology</i> , 2015, 4, e1016697.	4.6	11
268	Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. <i>Vaccines</i> , 2021, 9, 454.	4.4	11
269	Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. <i>Cancer Immunity</i> , 2002, 2, 14.	3.2	10
270	Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen. <i>International Journal of Cancer</i> , 1997, 72, 1045-1055.	5.1	9

#	ARTICLE	IF	CITATIONS
271	Therapeutic cancer vaccines based on molecularly defined human tumor antigens. <i>Vaccine</i> , 2002, 20, A2-A7.	3.8	9
272	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	9
273	Deciphering the unusual HLA-A2/Melan-A/MART-1 specific TCR repertoire in humans. <i>European Journal of Immunology</i> , 2014, 44, 2567-2570.	2.9	9
274	Disease-driven T cell activation predicts immune responses to vaccination against melanoma. <i>Cancer Immunity</i> , 2003, 3, 12.	3.2	8
275	Recombinant fusion proteins for targeting dendritic cell subsets in therapeutic cancer vaccine. <i>Methods in Enzymology</i> , 2020, 632, 521-543.	1.0	7
276	Human primed ILCPs support endothelial activation through NF- κ B signaling. <i>ELife</i> , 2021, 10, .	6.0	7
277	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. <i>European Journal of Immunology</i> , 1999, 29, 1990-1999.	2.9	7
278	N-acetyl-L-cysteine Exhibits Antitumoral Activity by Increasing Tumor Necrosis Factor γ -Dependent T-Cell Cytotoxicity. <i>Blood</i> , 1997, 90, 1124-1132.	1.4	7
279	Lack of Functionally Active Melan-A26 α 35-Specific T Cells in the Blood of HLA-A2+ Vitiligo Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1977-1980.	0.7	6
280	What is the influence of vaccination α routes on the regression of tumors located at mucosal sites?. <i>OncolImmunology</i> , 2012, 1, 242-243.	4.6	6
281	An optimized antigen α protein fusion. <i>Nature Biomedical Engineering</i> , 2020, 4, 583-584.	22.5	6
282	Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. <i>Tissue Antigens</i> , 1999, 53, 519-526.	1.0	5
283	Tinkering with Nature: The Tale of Optimizing Peptide Based Cancer Vaccines. , 2005, 123, 267-291.		5
284	Structured reporting of T cell assay results. <i>Cancer Immunity</i> , 2013, 13, 13.	3.2	5
285	Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. <i>International Journal of Cancer</i> , 2002, 99, 201-206.	5.1	4
286	On the significance of CD8 α expression for T cell memory. <i>European Journal of Immunology</i> , 2005, 35, 3092-3094.	2.9	4
287	The role of the reporting framework MIATA within current efforts to advance immune monitoring. <i>Journal of Immunological Methods</i> , 2014, 409, 6-8.	1.4	4
288	CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 209-214.	2.8	4

#	ARTICLE	IF	CITATIONS
289	Prediction of Cross-Recognition of Peptide-HLA A2 by Melan-A-Specific Cytotoxic T Lymphocytes Using Three-Dimensional Quantitative Structure-Activity Relationships. PLoS ONE, 2013, 8, e65590.	2.5	3
290	The Vast Universe of T Cell Diversity: Subsets of Memory Cells and Their Differentiation. Methods in Molecular Biology, 2017, 1514, 1-17.	0.9	3
291	Recognition of tumor-associated antigens by T-lymphocytes: Perspectives for peptide-based vaccines. Annals of Oncology, 1996, 7, 339-342.	1.2	2
292	Degeneracy instead of specificity: is this a solution to cancer immunotherapy?. Trends in Immunology, 2002, 23, 344.	6.8	2
293	Tumor Cell Recognition Efficiency by T Cells. PLoS Medicine, 2005, 2, e77.	8.4	2
294	Announcing the Tumor Immunology and Biological Cancer Therapy section (edited by iSBTc) of the Journal of Translational Medicine. Journal of Translational Medicine, 2009, 7, 80.	4.4	2
295	JTMs Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section. Journal of Translational Medicine, 2013, 11, 2.	4.4	2
296	Successful engineering cancer immunotherapy. European Journal of Immunology, 2014, 44, 318-320.	2.9	2
297	Detecting and analyzing murine innate lymphoid cells. Methods in Enzymology, 2020, 631, 329-342.	1.0	2
298	Moving cancer immunotherapy forward through the Journal for Immunotherapy of Cancer (JITC). , 2020, 8, e000001.		2
299	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2
300	Quantitative Multiparameter Assays to Measure the Effect of Adjuvants on Human Antigen-Specific CD8 T-Cell Responses. Methods in Molecular Biology, 2010, 626, 231-249.	0.9	2
301	An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immunity, 2008, 8, 6.	3.2	2
302	Circulating MELAN-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2 melanoma patients have a memory phenotype. International Journal of Cancer, 1998, 78, 699-706.	5.1	1
303	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. , 1999, 29, 1990.		1
304	Lack of tumor recognition by hTERT peptide 540-548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. , 2001, 31, 2642.		1
305	Melanoma Vaccines. , 2012, , 207-232.		0
306	JITC launches a new section: commentary and editorials. , 2015, 3, 28.		0

#	ARTICLE	IF	CITATIONS
307	Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer. , 2015, 3, 49.		0
308	CD8 T Lymphocytes in Antitumor Immunity. , 2016, , 434-440.		0
309	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
310	Generation of affinity ranged antigen-expressing tumor cell lines. Methods in Enzymology, 2020, 632, 503-519.	1.0	0
311	Assessment of memory formation by metabolically engineered antigen-specific CD8 T cells. Methods in Enzymology, 2020, 631, 77-90.	1.0	0
312	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. Blood, 2015, 126, 1019-1019.	1.4	0
313	Modulation of proteasomal activity in vitro induces the generation of an HLA-A*0201 specific CTL-defined epitope derived from the melanoma-associated antigen MAGE-3. , 2002, , 693-694.		0